Several multicenter trials conducted around the world have compared the efficacy and safety of bevacizumab and ranibizumab for treating wet AMD. In this presentation from Retina Subspecialty Day, Dr. Dan Martin provides a synopsis of the topline findings from four comparative studies, concluding that no study has shown a clinically significant difference between ranibizumab and bevacizumab.